Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Herpes Zoster Vaccine in Healthy Adults Aged 40 Years and Above
NCT07920172Phase 2Recruiting
- Sponsor
- Zhifei Biological
- Start
- Nov 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in herpes zoster (HZ) (7 arms), sponsored by Zhifei Biological. Primary endpoints: Adverse Events at 30 days, Serious Adverse Events at 12 months and 10 more. Started Nov 2026; status: recruiting.
02
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT07920172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920172.